Anavex Life Sciences Corp (AVXL)

[Jonjones325]

From the conference call. Please note the portion I placed in quotes about the super responders and patients. This tells me that it is the patient type that affected the outcome more and not the amount of drug or combination of. Thoughts? Am I reading too much into this?

The other thing is that we did identify so called very good responders even in this not optimally dosed situation and they have improved the cognition scores and function significantly and that has been described in the presentation from Saturday. And we are actually now looking into those, I would say, improved scores. That means they not only stabilize the disease, they actually improved from where they started from. So that is extremely impressive and that is what Dr. Perry’s reaction.

"""""""""""""So we will learn exactly what are the features of these patients, which will allow us now to optimally design the patient population in the future trial,""""""""""""""""" since we obviously are measuring against a placebo control, which will have standard of care, so we want to make sure that the delta between the decline and of now the stabilization or even improvement is as high as possible.

The patient type may have not affected the outcome MORE but it is an important variable in the anlysis of the results.